COMPUGEN, a drug and diagnostic discovery company, incorporates ideas and methods from mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine increasing the success of drug and diagnostic development. Compugen went public on NASDAQ in August 2000.     IMPELLA is an innovative high-tech enterprise which manufactures and markets intracorporeal micro blood pumps for use in coronary surgery and cardiology. Abiomed acquired Impella for $92 million in May 2005.     ORIDION is an innovator in the areas of respiratory patient monitoring systems and breath testing analyzers. Oridion went public on the Swiss SWX New Market Exchange in April 2000.     X TECHNOLOGIES developed a revolutionary balloon angioplasty device designed to address several pressing needs in the coronary angioplasty and stenting market. Acquired by Guidant in March 2003.     ICECURE MEDICAL develops innovative, minimally invasive Cryo-therapy products, for the treatment of breast tumors and other internal diseased tissue.     BIOLINERX is a bio- pharmaceutical drug development company that in-licenses compounds primarily from Israeli academia and hospitals and takes these molecules to a higher valuation in future royalty streams by filling the gap in the developmental phase.     CAN-FITE focuses on drugs for treating cancer and inflammatory diseases providing drugs that are highly efficacious in their therapeutic activity but devoid of some of the major shortcomings inherent in many of the drug therapies currently available.     CIRCULITE is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive micro-pumps for long term partial circulatory support. By enabling a proactive and lower-risk treatment approach, supplementing a patient's pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients.     INTELLIDX is a medical technology company that is developing an automated, bedside blood analyzer for use in the critical care units. The OPTIMUS® Monitoring System automatically samples micro quantities of whole blood from a patient’s IV line and performs frequent measurements of various blood constituents at required intervals. The Unit monitors and reports test measurements around the clock.     Combining surgical precision with interventional therapy, MITRALIGN is developing an innovative, catheter-based method to effectively treat mitral regurgitation in patients suffering from Congestive Heart Failure. Mitralign's goal is to emulate the technique employed in traditional open heart surgical repair but in a far less invasive manner.     PATHWAY develops medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. Pathway’s Jetstream™ Atherectomy Catheter allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing hard and soft plaque, calcium, thrombus, and fibrotic lesions.     PRONEURON focuses on cell therapy and neuroimmunology on the development and commercialization of treatments for spinal cord injuries (SCI) as well as other neurological disorders.     PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing unique technology and knowledge of the ubiquitin system.     ULTRASPECT specializes in the development, production and sale of products dedicated to the enhancement of imaging quality and productivity performance of NM Gamma Cameras. Based on its proprietary, innovative reconstruction algorithms technology, Wide-Beam Reconstruction (WBRTM), the Company's imaging solutions shorten acquisition times and increase image resolution.     NAVOTEK develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the Oncology area, providing tumor localization and tracking for optimal radiation therapy.